Skip to search formSkip to main contentSkip to account menu

etirinotecan pegol

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Heterocyclic Compounds, 4 or More RingsPolyethylene Glycols

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer
ABSTRACT Introduction: A PEGylated form of irinotecan, a topoisomerase I inhibitor, is now available in commerce; its safety and… 
2018
2018
Abstract OT2-07-10: ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases…
Background: EP is a next generation topoisomerase I inhibitor-polymer conjugate that provides continuous exposure to SN-38, the… 
2017
2017
ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously…
TPS1120Background: EP is a next generation topoisomerase I inhibitor-polymer conjugate that provides continuous exposure to SN-38… 
Review
2016
Review
2016
Etirinotecan pegol for the treatment of breast cancer
ABSTRACT Introduction: Advanced breast cancer is incurable for most patients with limited therapeutic options. As such, there is… 
2016
2016
Abstract P1-13-02: Early change in topoisomerase 1 (Top1) positive circulating tumor cells (CTCs) is associated with overall survival (OS) in patients with advanced breast cancer after treatment with…
Background: Etirinotecan pegol (EP) is a long-acting Top1 inhibitor providing sustained levels of active metabolite throughout… 
2016
2016
Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM)
2014
2014
Abstract 4592: Etirinotecan pegol accumulates in breast cancer brain metastases and prolongs survival in an experimental model of brain metastases of human triple negative breast cancer
Background: Breast cancer brain metastases (BCBM) remain a challenging consequence of advanced breast cancer. The blood-brain… 
2013
2013
Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast…
1087 Background: EP is a unique topoisomerase 1 inhibitor that provides continuous exposure to SN38. EP demonstrated a 29… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)